Doxy-PEP Adoption Grows, But 2026 Guidance Requires Regular STI Screening to Go With It

January 26, 2026

Doxycycline post-exposure prophylaxis, commonly known as doxy-PEP, has continued to expand as a bacterial STI prevention tool since CDC first issued formal guidance in June 2024, but 2026 clinical protocols make clear that the strategy is not a substitute for regular testing.

Doxy-PEP involves taking a single 200-milligram dose of doxycycline within 72 hours of condomless sex. Three large randomized controlled trials cited in CDC's guidance found the approach reduced syphilis and chlamydia infections by more than 70% and gonorrhea infections by roughly 50%.

CDC recommends doxy-PEP specifically for men who have sex with men and transgender women who have had a bacterial STI diagnosed within the past 12 months, following a shared decision-making conversation with a healthcare provider.

According to 2026 clinical protocol guidance reviewed by health information platform Pabau, patients using doxy-PEP are required to undergo STI screening at least every three months, with some clinics implementing quarterly schedules based on individual risk profiles. CDC's original guidance similarly calls for bacterial STI testing at exposure sites at baseline and every three to six months thereafter.

Efficacy against gonorrhea specifically has varied by region, according to the guidance, depending on local rates of tetracycline-resistant Neisseria gonorrhoeae. Public health researchers have also flagged ongoing concern about whether wider doxy-PEP use could contribute to antibiotic resistance over time, a question that continues to be studied.

Anyone on a doxy-PEP regimen — or simply following a routine testing schedule — can use the testing window calculator to time their next screening appropriately.

Sources: CDC MMWR Guidance, Pabau Clinical Review.